AG Tong announced a significant development in one of the ongoing generic drug price-fixing cases, sharing that U.S. District Judge Shea Michael P. Shea dismissed a motion for summary judgment filed by the drugmakers seeking to toss key elements of the case.

Connecticut is leading a coalition of nearly all states and territories in three antitrust lawsuits. The first Complaint, filed in 2016, included Heritage and 17 other corporate Defendants, two individual Defendants, and 15 generic drugs. The second Complaint was filed in 2019 against Teva Pharmaceuticals and 19 of the nation’s largest generic drug manufacturers. The Complaint names 16 individual senior executive Defendants. The third complaint, to be tried first, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and names 26 corporate defendants and 10 individual defendants.

“The drugmakers have sought to chip away at our case piece by piece, but this latest ruling preserves our claims and reflects the strength of our case heading into the first trial in Connecticut. Generic drug manufacturers engaged in a brazen, industrywide conspiracy to fix prices and allocate market share for medicines we rely on every day. Our case seeks to hold them accountable and restore fairness to this broken system." -AG Tong